Risk Factors for Acute Kidney Injury in Visceral Leishmaniasis (Kala-Azar)

Michelle J. C. Oliveira, Geraldo B. Silva Júnior, Krasnalhia Lívia S. Abreu, Natália A. Rocha, Ana Valeska V. Garcia, Luiz F. L. G. Franco, Rosa M. S. Mota, Alexandre B. Libório, and Elizabeth F. Dahera

Post-Graduation Program in Medical Sciences, Department of Internal Medicine, School of Medicine, Federal University of Ceará; Division of Nephrology, Department of Internal Medicine, School of Medicine, Walter Cantídio University Hospital, Federal University of Ceará; Department of Statistics, Science Center, Federal University of Ceará; Discipline of Nephrology, School of Medicine, University of Fortaleza, Fortaleza, Ceará, Brazil

Abstract. The aim of this study was to investigate the factors associated with acute kidney injury (AKI) in patients with visceral leishmaniasis (VL). The study patients had a diagnosis of VL and were admitted to a tertiary hospital. A multivariate analysis was performed to analyze the risk factors for AKI. A total of 224 patients were included. The mean age was 36 ± 15 years. AKI was observed in 33.9% of cases. Risk factors associated with AKI were male gender (odds ratio [OR] = 2.2; P = 0.03), advanced age (OR = 1.05; P < 0.001), and jaundice (OR = 2.9; P = 0.002). There was an association between amphotericin B use and AKI (OR = 18.4; P < 0.0001), whereas glucantime use was associated with lower incidence of AKI compared with amphotericin B use (OR = 0.05; P < 0.0001). Mortality was 13.3%, and it was higher in AKI patients (30.2%). Therefore, factors associated with AKI were male gender, advanced age, and jaundice. Amphotericin B was an important cause of AKI in VL.

INTRODUCTION

Visceral leishmaniasis (VL) is an endemic disease in tropical and subtropical countries, as well as in southern Europe, affecting 1–2 million individuals and causing ~500,000 new cases and 5,000 deaths each year.1–4 It is a vector-borne disease caused by different species of Leishmania parasites.1,5,6 As a consequence of the intense parasitism of the reticular endothelial system, kala-azar patients present with marked anemia, leukopenia, and thrombocytopenia, as well as increased plasmatic levels of gamma globulins.7

Renal abnormalities caused by Leishmania have been well-documented in experimental animal studies and are comprised of interstitial and glomerular abnormalities.7 There have been few human studies on renal function in VL. The main pathophysiological mechanism by which VL affects the kidneys probably includes immune-complex disease, which is similar to other parasitic infections such as malaria and schistosomiasis. Most patients present proliferative glomerulonephritis and interstitial nephritis.7 Studies on acute kidney injury (AKI) in VL are rare. Possible causes for AKI in VL include drug toxicity, associated infections, hemodynamic abnormalities, and VL itself.8–12

The aim of this study was to investigate the prevalence, clinical manifestations, and risk factors associated with AKI in patients with VL.

PATIENTS AND METHODS

The study was carried out from December 2002 to December 2008 and included patients with a clinical and laboratory diagnosis of VL admitted to São José Hospital of Infectious Diseases in the city of Fortaleza, state of Ceará, Brazil. All patients had the diagnosis of VL based on the identification of amastigotes in smears obtained from sternal bone-marrow aspirate, and some patients underwent rk39 antigen tests during active infection. A standardized case-investigation form was used to complete demographical, epidemiological, clinical, and laboratory data. Patients with age ≤ 14 years, previous renal insufficiency, arterial hypertension, diabetes mellitus, and co-morbidities that could affect renal function during the study were excluded.

Definitions. Oliguria was considered to be present when the urinary volume was < 400 mL/day despite appropriate fluid replacement. Hypotension was defined as mean arterial blood pressure (MAP) < 60 mmHg, and therapy with vasoactive drugs was initiated when MAP was lower than 60 mmHg. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) at admission were also analyzed. Metabolic acidosis was defined as pH < 7.35 and arterial bicarbonate < 20 mEq/L; coagulation abnormalities were defined as platelet count < 100 × 10^3/mm^3 and prothrombin time lower than 65%. Hypoalbuminemia was defined as serum albumin < 3.5 g/dL, anemia was defined as Hb ≤ 12 g/dL, and leukopenia was defined as white blood cells (WBC) < 3,500 mm^3.

Group definition. The population was divided in two groups: patients with normal renal function (non-AKI) and patients with AKI; these groups were defined according to creatinine levels by applying the RIFLE (risk, injury, failure, loss, end-stage renal disease) criteria13 and were established during hospital stay. We compared these two groups to investigate the differences in clinical manifestations, laboratory features, and risk factors for AKI.

Protocol of treatment. Patients with VL were treated with intravenous injections of pentavalent antimonials (Glucantime; Sanofi-Aventis, São Paulo, Brazil) 20 mg/kg daily for 20–40 consecutive days, and in severe cases, amphotericin B was given at a 7–20 mg/kg total dose for up to 20 days. None of the patients included in the study received the lipid formulation of amphotericin B. Patients with secondary bacterial infections received antibiotic therapy.

Ethics. The study was approved by the Ethics Committee of São José Hospital of Infectious Diseases.

Statistical analyses. The results and means ± standard deviations for quantitative variables are presented in Tables 1–4. The univariate and multivariate analyses of the clinical and laboratory data were performed using the SPSS package version 10.0 (SPSS Inc., Chicago, IL) and Epi Info version 6.04b (Centers for Disease Control and Prevention, Atlanta,
coughing (41.5%), headache (34.8%), abdominal pain (34.8%),

The main signs and symptoms of the patients were males. Mean hospital stay was 18 ± 11 days (range = 1–69 days). The comparison between AKI and non-AKI patients is summarized in Tables 1 and 2. AKI patients presented higher levels of urea, creatinine, potassium, direct bilirubins, and indirect bilirubins, as well as a higher number of WBCs. Sodium, HCO₃⁻, pCO₂, albumin levels, platelets count, and prothrombin time were lower in AKI compared with non-AKI patients. The factors associated with AKI were male gender, advanced age, jaundice, and use of amphotericin B, and these results are summarized in Table 3.

The second choice of treatment for severe VL is amphotericin B, a nephrotoxic drug. We observed a significant association between the use of amphotericin B and AKI (P < 0.0001) in patients with the severe form of VL that did not respond to glucantime. AKI was observed in 39 patients using amphotericin B (82.9% of the patients receiving the drug, which corresponds to 17.4% of all studied patients). The percentage of patients that received glucantime and had AKI was 20.9%. All patients in the AKI group treated with amphotericin B had normal serum creatinine levels at admission. The use of glucantime was associated with a lower incidence of AKI (P < 0.0001) as shown in Table 4.

Overall mortality was 30 (13.3%). Mortality was significantly higher in AKI patients with 23 deaths (30.2%) compared with 7 deaths in the non-AKI group (3.1%; P < 0.0001). The causes of death were respiratory failure in 13 cases (43.4%), septic shock in 10 (33.3%), hepatic failure in 4 (13.3%), and kidney failure in 3 (10%). The risk factors for death were amphotericin B use (OR = 3.1; 95% CI = 1.36–7.0; P = 0.02), jaundice (OR = 9.94; 95% CI = 1.59–62.3; P = 0.02), and dyspnea (OR = 17.9; 95% CI = 3.3–97.2; P = 0.001). Mortality was also higher among patients using amphotericin B (25.6% versus 9.7%; P = 0.003) as illustrated in Figure 2.

DISCUSSION

Human VL is an endemic parasitic infection in Brazil that has reemerged, especially in peri-urban areas. Renal involvement is considered rare, presenting as hematuria, proteinuria, or renal-function impairment. There is little information on AKI in VL. A prospective study showed renal impairment in only 1 of 11 patients (11%) when considering serum creatinine (Scr) levels higher than 1.3 mg/dL. The present study found a higher incidence of AKI (33.9%) in patients with a confirmed diagnosis of VL.

In a recent study carried out by our group, AKI (considered as serum creatinine levels higher than 1.3 mg/dL) was found in 26.2% of 57 patients with VL. Lima Verde and others in a cross-sectional study of 50 consecutive patients with visceral leishmaniasis, also carried out in our region, found a decreased glomerular filtration rate in 28% of the cases; this rate was attributed to fluid loss, volume contraction, and immunologic glomerular disease.
Comparison of admission laboratory data between AKI and non-AKI patients with VL

<table>
<thead>
<tr>
<th>Parameter</th>
<th>AKI (N = 76)</th>
<th>Non-AKI (N = 148)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urea (mg/dL)</td>
<td>58 ± 46 (10–238)</td>
<td>30 ± 10 (13–91)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Creatinine (mg/dL)</td>
<td>1.8 ± 1.8 (0.5–8.6)</td>
<td>0.8 ± 0.2 (0.4–1.4)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Sodium (mEq/L)</td>
<td>132 ± 4.7 (119–139)</td>
<td>133 ± 4.2 (119–142)</td>
<td>0.04</td>
</tr>
<tr>
<td>Potassium (mEq/L)</td>
<td>4.2 ± 0.7 (2.7–5.9)</td>
<td>4.0 ± 0.5 (1.9–5.5)</td>
<td>0.02</td>
</tr>
<tr>
<td>HCO₃ (mEq/L)</td>
<td>15 ± 5.8 (7.7–26.2)</td>
<td>21 ± 8.8 (18.3–35)</td>
<td>0.04</td>
</tr>
<tr>
<td>Arterial pH</td>
<td>7.35 ± 0.12 (7.14–7.54)</td>
<td>7.44 ± 0.10 (7.44–7.49)</td>
<td>0.10</td>
</tr>
<tr>
<td>pO₂ (mmHg)</td>
<td>104 ± 29 (48.9–192.5)</td>
<td>101 ± 29 (75–111)</td>
<td>0.81</td>
</tr>
<tr>
<td>pCO₂ (mmHg)</td>
<td>25 ± 8.1 (14.3–47.3)</td>
<td>32 ± 7.1 (24–37)</td>
<td>0.04</td>
</tr>
<tr>
<td>SatO₂ (%)</td>
<td>95 ± 4.7 (82–99.6)</td>
<td>97 ± 0.9 (96–98)</td>
<td>0.30</td>
</tr>
<tr>
<td>Fasting glucose (mg/dL)</td>
<td>109 ± 50 (65–347)</td>
<td>106 ± 26 (46–200)</td>
<td>0.66</td>
</tr>
<tr>
<td>Amylase (UI/L)</td>
<td>85 ± 64 (41–199)</td>
<td>92 ± 53 (28–178)</td>
<td>0.80</td>
</tr>
<tr>
<td>LDH (UI/L)</td>
<td>1,626 ± 1,348 (109–5,827)</td>
<td>1,056 ± 1,032 (127–541)</td>
<td>0.23</td>
</tr>
<tr>
<td>Total bilirubin (g/dL)</td>
<td>6.1 ± 7.9 (0.4–22)</td>
<td>1.2 ± 1.6 (0.4–5)</td>
<td>0.07</td>
</tr>
<tr>
<td>Direct bilirubin (g/dL)</td>
<td>4.5 ± 6.1 (0.08–17.8)</td>
<td>0.8 ± 1.6 (0.8–4.47)</td>
<td>0.03</td>
</tr>
<tr>
<td>Albumin (g/dL)</td>
<td>1.5 ± 2.0 (0.06–7)</td>
<td>0.4 ± 0.2 (0.2–0.8)</td>
<td>0.009</td>
</tr>
<tr>
<td>AST (UI/L)</td>
<td>2.5 ± 0.8 (0.9–4.5)</td>
<td>2.8 ± 0.7 (0.6–4.5)</td>
<td>0.01</td>
</tr>
<tr>
<td>ALT (UI/L)</td>
<td>199 ± 339 (12–2,161)</td>
<td>101 ± 122 (14.3–804)</td>
<td>0.11</td>
</tr>
<tr>
<td>AP (UI/L)</td>
<td>225 ± 342 (4–1,071)</td>
<td>143 ± 215 (60–603)</td>
<td>0.57</td>
</tr>
<tr>
<td>Ht (%)</td>
<td>439 ± 312 (363–1,240)</td>
<td>455 ± 368 (45–1,759)</td>
<td>0.89</td>
</tr>
<tr>
<td>Hb (g/dL)</td>
<td>25 ± 5.2 (13.9–39.6)</td>
<td>25 ± 5.1 (9.4–31)</td>
<td>0.40</td>
</tr>
<tr>
<td>WBC (mm³)</td>
<td>83,813 ± 71,801 (6,000–493,000)</td>
<td>90,856 ± 67,545 (1,000–470,000)</td>
<td>0.04</td>
</tr>
<tr>
<td>Platelets (mm³)</td>
<td>107 ± 41 (17.1–100)</td>
<td>79 ± 35 (3–140)</td>
<td>0.07</td>
</tr>
<tr>
<td>Prothrombin time (%)</td>
<td>56 ± 21 (17.1–100)</td>
<td>62 ± 19 (10.6–100)</td>
<td>0.01</td>
</tr>
</tbody>
</table>

LDH = lactate dehydrogenase; AST = aspartate aminotransferase; ALT = alanineaminotransferase; AP = alkaline phosphatase; Ht = hematocrit; Hb = hemoglobin; HSR = hemosedimentation rate.

Hematuria was seen in 4.5% of cases, even in patients without AKI, suggesting a possible glomerular involvement. Urinary-sediment alterations and decreased renal function have been described in patients with VL. In a prospective study of 50 patients with VL, urinary-sediment alterations with hematuria and leukocyturia were found in 51% of the studied cases. Slightly increased urinary-protein excretion was observed in 24-hour urine samples from 57.1% of these patients. A high percentage of urinary abnormalities, including macroscopic hematuria (45.4%), proteinuria (90.9%), and leukocyturia (54.5%), were observed in a prospective study of 11 patients with VL from Brazil. Mesangial deposits, mesangial cell hyperplasia, and glomerular endothelial cell tumefaction have been found in histopathological studies of patients with VL and in dogs that were naturally infected. All patients submitted to autopsy presented mononuclear interstitial nephritis, edema, and focal tubular degeneration. Acute glomerulonephritis, nephrotic syndrome, acute interstitial nephritis, and renal failure have also been described in VL.

In the present study, the use of amphotericin B was an important risk factor for AKI in VL, and it was associated with an 18-fold increased risk of developing AKI. In a recent study with 48 patients receiving amphotericin B, AKI (defined as an increase of $>50$% in basal creatinine levels) occurred in 31% of cases. Higher incidences of AKI secondary to the use of amphotericin B have been reported, with percentages as high...
In the present study, meglumine antimoniate was the first-choice treatment used in 80% of patients receiving this drug. In the present study, AKI developed in a high number of patients receiving amphotericin B (82.9%). Moreover, amphotericin B was also associated with a higher mortality rate, with 3-fold increased risk of death. AKI was significantly less frequent among patients treated with a higher mortality rate, with 3-fold increased risk of death. AKI was significantly less frequent among patients using glucantime. Since 1940, the pentavalent antimony compounds sodium stibogluconate and meglumine antimoniate (glucantime) have been the mainstays of antileishmanial therapy. In the present study, meglumine antimoniate was the first-choice treatment used in > 88% of cases. New therapeutic options, including oral drugs such as miltefosine, are being considered, as shown in recent studies.

In the present study, overall mortality was 13.3%, and it was significantly higher in AKI patients (30.2% versus 4.7%). There have been few studies on mortality in VL. In a previous study by our study group, the mortality rate was lower (5.2% of 57 study patients), and all deaths were associated with AKI. A study of prognostic factors conducted in Northeastern Brazil verified that severe anemia, fever lasting > 60 days, diarrhea, and jaundice were risk factors for death in VL. In the present study, the risk factors for mortality were amphotericin B use, oliguria, jaundice, and dyspnea. Mortality was also higher among patients using amphotericin B (25.6% versus 9.7%), and this could be caused by the higher severity of the disease in patients who required the use of amphotericin B (VL-associated resistant infection or VL-associated severe leukopenia and sepsis).

In conclusion, AKI is an important complication in VL that seems to increase mortality. The predictive factors associated with AKI were male gender, advanced age, and jaundice. Amphotericin B is an important cause of AKI in VL, showing that nephrotoxicity plays an important role in the pathogenesis of AKI in this disease. Mortality was higher in AKI patients.

**REFERENCES**


